These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17646047)

  • 1. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.
    Bella AJ; Deyoung LX; Al-Numi M; Brock GB
    Eur Urol; 2007 Oct; 52(4):990-1005. PubMed ID: 17646047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel indications for phosphodiesterase type 5 inhibitors].
    Rosenkranz S; Caglayan E; Erdmann E
    Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
    Kapur V; Chien CV; Fuess JE; Schwarz ER
    Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
    Francis SH; Morris GZ; Corbin JD
    Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
    Greco EA; Spera G; Aversa A
    Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.
    Fusco F; Razzoli E; Imbimbo C; Rossi A; Verze P; Mirone V
    BJU Int; 2010 Jun; 105(12):1634-9. PubMed ID: 20553468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase type 5 inhibitors: the day after.
    Hatzimouratidis K; Hatzichristou D
    Eur Urol; 2007 Jan; 51(1):75-88; discussion 89. PubMed ID: 16949200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current management of erectile dysfunction after cancer treatment.
    Peltier A; van Velthoven R; Roumeguère T
    Curr Opin Oncol; 2009 Jul; 21(4):303-9. PubMed ID: 19509501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.
    Rambhatla A; Kovanecz I; Ferrini M; Gonzalez-Cadavid NF; Rajfer J
    Int J Impot Res; 2008; 20(1):30-4. PubMed ID: 17673932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.
    Burnett AL
    J Androl; 2008; 29(1):3-14. PubMed ID: 17942972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
    Patel MD; Katz SD
    Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
    Mehrotra N; Gupta M; Kovar A; Meibohm B
    Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
    Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PDE5 inhibitors and satisfaction of patients with erectile dysfunction].
    Cour F
    Prog Urol; 2008 Sep; 18(8):542. PubMed ID: 18760745
    [No Abstract]   [Full Text] [Related]  

  • 18. PDE5 inhibitors: is there more to come besides erectile dysfunction?
    Stief C
    Eur Urol; 2007 Oct; 52(4):943-4. PubMed ID: 17683851
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy.
    Salonia A; Gallina A; Zanni G; Briganti A; Dehò F; Saccà A; Suardi N; Barbieri L; Guazzoni G; Rigatti P; Montorsi F
    Eur Urol; 2008 Mar; 53(3):564-70. PubMed ID: 17761385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.